title: False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam.
abstract: In this prospective study including 78 adult patients with haematological malignancy (90 episodes) we performed galactomannan (GM) (Platelia Aspergillus) screening twice weekly for the diagnosis of invasive aspergillosis. There were five proven and four probable invasive aspergillosis cases. The sensitivity, specificity and positive and negative predictive values were 100, 88, 47 and 100%, respectively. There were eight patients with false positive GM (10.2%). In six patients the false GM reactivity was due to the administration of piperacillin-tazobactam (P-T). A significant association was found between false positive GM (= or > 0.5) and the administration of P-T (p < 0.01). Two other patients with no invasive aspergillosis (2.5%) and false GM reactivity had graft versus host disease (GVHD) and one of them had also mucositis grade IV. The kinetic patterns of false positive GM due to P-T is discussed.
authors.affiliation: Servicio de Microbiología, Unidad de Micología, Hospital Universitario Doce de Octubre, Avenida del Córdoba s/n, 28041 Madrid, Spain.
authors.forename: Almudena
authors.initials: A
authors.lastname: Alhambra
authors.forename: María Soledad
authors.initials: MS
authors.lastname: Cuétara
authors.forename: María Cruz
authors.initials: MC
authors.lastname: Ortiz
authors.forename: Juan Marcos
authors.initials: JM
authors.lastname: Moreno
authors.forename: Angel
authors.initials: A
authors.lastname: del Palacio
authors.forename: José
authors.initials: J
authors.lastname: Pontón
authors.forename: Amalia
authors.initials: A
authors.lastname: del Palacio
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016477:Artifacts; D001228:Aspergillosis / Q000097:blood / Q000175:diagnosis*; D015415:Biomarkers; D003131:Combined Modality Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005189:False Positive Reactions; D005260:Female; D016469:Fungemia / Q000097:blood / Q000175:diagnosis*; D005690:Galactose / Q000031:analogs & derivatives; D006086:Graft vs Host Disease / Q000097:blood / Q000150:complications; D019337:Hematologic Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000601:surgery; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008351:Mannans / Q000097:blood*; D008875:Middle Aged; D052016:Mucositis / Q000097:blood / Q000150:complications; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010878:Piperacillin / Q000494:pharmacology / Q000627:therapeutic use; D000077725:Piperacillin, Tazobactam Drug Combination; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012680:Sensitivity and Specificity
chemical_list: D000900:Anti-Bacterial Agents; D015415:Biomarkers; D008351:Mannans; C012990:galactomannan; D000077725:Piperacillin, Tazobactam Drug Combination; D010397:Penicillanic Acid; D010878:Piperacillin; D005690:Galactose